Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stocks Tumble On Tetraphase, Flexion Failures; Surge On Akebia Win

This article was originally published in Scrip

Executive Summary

Antibiotic developer Tetraphase Pharmaceuticals Inc. and arthritis pain drug maker Flexion Therapeutics Inc. were battered in after-hours trading on Sept. 8 after the companies said their lead drug candidates failed to reach statistical significance in late-stage clinical trials, but investors rewarded Akebia Therapeutics Inc. for positive mid-stage results for its anemia drug after the stock market closed.

Advertisement

Related Content

Tetraphase Bets On I.V. Eravacycline Rerun As Antibiotic Market Influx Looms

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC029706

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel